SCHEMBL6992810

SCHEMBL6992810

CC(=O)C1NS(=O)(=O)c2ccc(Cl)cc2C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.49
DAPK3 O43293 1/20 0.49
MAP4K4 O95819 1/20 0.49
RET P07949 1/20 0.49
PIM1 P11309 1/20 0.49
LTK P29376 1/20 0.49
GRK5 P34947 1/20 0.49
CSNK1A1 P48729 1/20 0.49
CDK8 P49336 1/20 0.49
PRKX P51817 1/20 0.49
LIMK1 P53667 1/20 0.49
CDK5 Q00535 1/20 0.49
ACVR1 Q04771 1/20 0.49
PTK2 Q05397 1/20 0.49
TYRO3 Q06418 1/20 0.49
PRKAA1 Q13131 1/20 0.49
DYRK1A Q13627 1/20 0.49
NTRK3 Q16288 1/20 0.49
LRRK2 Q5S007 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6988782 0.91 KDM4E (0.44) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL6994911 0.81 L3MBTL1 (0.41) CYP1A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL9786880 0.79 CA2 (0.47) KDM4EALDH1A1HSD17B10CA2CA12
SCHEMBL6988202 0.72 CA9 (0.42) CYP1A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL6996064 0.71 RET (0.49) RETGRK5TYRO3DYRK1BCYP1A2
SCHEMBL31536405 0.69 CA1 (0.47) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL3984666 0.66 RET (1.00) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL11641208 0.65 CA12 (0.49) CHEK1KDM4EALDH1A1CA2CA12
SCHEMBL6997184 0.64 KCNA5 (0.37) PIM1KDM4ECA2CA12CA9
SCHEMBL11487687 0.64 CHEK1 (0.54) CHEK1DAPK3MAP4K4RETPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6664251-B2 Serotonin receptor antagonist; treating cardiovascular disorder DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-12-16 US disclosed
US-20030078256-A1 Benzothiazine derivative SUNTORY LIMITED (JP) 2003-04-24 US disclosed
EP-0749967-B1 Substituted benzothiazine derivative SUNTORY LTD (JP) 2003-01-22 EP disclosed
US-6316442-B1 TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES SUNTORY LIMITED (JP) 2001-11-13 US disclosed
US-6001827-A Benzothiazine derivative SUNTORY LIMITED (JP) 1999-12-14 US disclosed
US-5874429-A ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS SUNTORY LIMITED (JP) 1999-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078256-A1 Benzothiazine derivative TPH2, ADRB2, TPH1 CHEK1 2647/4885DAPK3 2992/4885MAP4K4 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.